Tumor relapse in patients with ER+ breast cancer is thought to emerge either from expansion of preexistent drug-resistant clones without any intermediate dormancy (16, 22, 23) or by de novo mechanisms appearing under therapeutic pressure during dormancy (1, 2, 13, 17). Here, ESR1 is linked to breast carcinoma.